当前位置：
X-MOL 学术
›
J. Antimicrob. Chemother.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Evaluation of the in vitro activity of new polymyxin B analogue SPR206 against clinical MDR, colistin-resistant and tigecycline-resistant Gram-negative bacilli.
Journal of Antimicrobial Chemotherapy ( IF 3.9 ) Pub Date : 2020-06-26 , DOI: 10.1093/jac/dkaa217 Yawei Zhang 1 , Chunjiang Zhao 1 , Qi Wang 1 , Xiaojuan Wang 1 , Hongbin Chen 1 , Henan Li 1 , Feifei Zhang 1 , Hui Wang 1
Journal of Antimicrobial Chemotherapy ( IF 3.9 ) Pub Date : 2020-06-26 , DOI: 10.1093/jac/dkaa217 Yawei Zhang 1 , Chunjiang Zhao 1 , Qi Wang 1 , Xiaojuan Wang 1 , Hongbin Chen 1 , Henan Li 1 , Feifei Zhang 1 , Hui Wang 1
Affiliation
SPR206 is a novel polymyxin analogue. Activity against clinical isolates is little documented.
中文翻译：
评估新的多粘菌素B类似物SPR206对临床耐多药耐药，大肠菌素耐药和替加环素耐药的革兰氏阴性杆菌的体外活性。
SPR206是新型多粘菌素类似物。很少有针对临床分离株的活性记录。
更新日期：2020-08-24
中文翻译：
评估新的多粘菌素B类似物SPR206对临床耐多药耐药，大肠菌素耐药和替加环素耐药的革兰氏阴性杆菌的体外活性。
SPR206是新型多粘菌素类似物。很少有针对临床分离株的活性记录。
京公网安备 11010802027423号